Loading clinical trials...
Loading clinical trials...
A Phase III, Double-Blind, Placebo-Controlled, Randomized Study of Taselisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy
Conditions
Interventions
Taselisib
Placebo
+1 more
Locations
157
United States
Arizona Oncology
Tucson, Arizona, United States
Arizona Oncology Associates, P.C.
Tucson, Arizona, United States
Georgia Cancer Specialists - Northside
Atlanta, Georgia, United States
Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital
Marietta, Georgia, United States
Ingalls Hospital
Harvey, Illinois, United States
Maryland Oncology Hematology
Rochville, Maryland, United States
Start Date
April 9, 2015
Primary Completion Date
June 29, 2021
Completion Date
June 29, 2021
Last Updated
July 12, 2022
NCT04541381
NCT05468034
NCT03137095
NCT07040891
NCT06393374
NCT07547774
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions